Insider Selling: DexCom, Inc. (NASDAQ:DXCM) EVP Sells 500 Shares of Stock

Key Points

• Michael Jon Brown, EVP of DexCom, sold 500 shares of the company stock on August 15th for a total of $40,145, reducing his ownership by 0.53% to approximately 94,102 shares.
• DexCom recently reported a quarterly earnings per share (EPS) of $0.48, exceeding analysts' expectations and reflecting a 15.2% increase in year-over-year revenue.
• Analysts have a consensus rating of "Moderate Buy" for DexCom, with several upgrades post-earnings leading to price targets as high as $106.00.

DexCom, Inc. (NASDAQ:DXCM - Get Free Report) EVP Michael Jon Brown sold 500 shares of DexCom stock in a transaction dated Friday, August 15th. The stock was sold at an average price of $80.29, for a total value of $40,145.00. Following the sale, the executive vice president directly owned 94,102 shares in the company, valued at approximately $7,555,449.58. This trade represents a 0.53% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Michael Jon Brown also recently made the following trade(s):

• On Monday, June 16th, Michael Jon Brown sold 500 shares of DexCom stock. The stock was sold at an average price of $82.80, for a total value of $41,400.00.
• On Friday, May 23rd, Michael Jon Brown sold 10,000 shares of DexCom stock. The stock was sold at an average price of $84.28, for a total value of $842,800.00.

DexCom Trading Down 0.2%

NASDAQ:DXCM traded down $0.13 during trading hours on Monday, hitting $80.82. 2,976,710 shares of the stock were exchanged, compared to its average volume of 3,806,923. The company's 50 day moving average is $82.96 and its two-hundred day moving average is $79.95. DexCom, Inc. has a twelve month low of $57.52 and a twelve month high of $93.25. The company has a quick ratio of 1.35, a current ratio of 1.52 and a debt-to-equity ratio of 0.48. The company has a market capitalization of $31.69 billion, a P/E ratio of 56.13, a price-to-earnings-growth ratio of 1.70 and a beta of 1.43.

DexCom (NASDAQ:DXCM - Get Free Report) last posted its quarterly earnings data on Wednesday, July 30th. The medical device company reported $0.48 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.45 by $0.03. DexCom had a return on equity of 30.41% and a net margin of 13.29%. The firm had revenue of $1.16 billion for the quarter, compared to the consensus estimate of $1.13 billion. During the same quarter in the prior year, the business earned $0.43 EPS. The business's revenue for the quarter was up 15.2% compared to the same quarter last year. On average, sell-side analysts anticipate that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on the company. UBS Group lifted their price objective on DexCom from $105.00 to $106.00 and gave the company a "buy" rating in a report on Thursday, July 31st. Raymond James Financial lifted their price objective on DexCom from $99.00 to $102.00 and gave the company a "strong-buy" rating in a report on Thursday, July 31st. William Blair raised DexCom to a "strong-buy" rating in a report on Thursday, July 31st. Wall Street Zen downgraded DexCom from a "strong-buy" rating to a "buy" rating in a report on Sunday, August 10th. Finally, Canaccord Genuity Group reiterated a "buy" rating and issued a $106.00 target price on shares of DexCom in a research note on Friday, August 1st. Four equities research analysts have rated the stock with a hold rating, sixteen have given a buy rating and three have issued a strong buy rating to the stock. According to MarketBeat.com, DexCom presently has a consensus rating of "Moderate Buy" and a consensus price target of $99.89.

Institutional Trading of DexCom

Institutional investors and hedge funds have recently made changes to their positions in the business. Andra AP fonden bought a new stake in shares of DexCom in the 2nd quarter valued at $26,000. Twin Peaks Wealth Advisors LLC bought a new position in DexCom in the 2nd quarter valued at about $26,000. Golden State Wealth Management LLC raised its holdings in DexCom by 211.2% in the 1st quarter. Golden State Wealth Management LLC now owns 389 shares of the medical device company's stock valued at $27,000 after acquiring an additional 264 shares during the period. Zions Bancorporation National Association UT bought a new position in shares of DexCom during the first quarter worth approximately $27,000. Finally, Optiver Holding B.V. bought a new position in shares of DexCom during the fourth quarter worth approximately $33,000. Institutional investors own 97.75% of the company's stock.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.